CROI

CROI offers more than 1100 high-quality presentations and myriad poster sessions. You have so little time. Our CROI blogger offers 6 different ways to maximize learning at any jam-packed meeting, depending on your personal style.

The antiviral future holds great promise for people living with HIV: better-tolerated, less toxic, drugs are about to come to market, and we are about to see the introduction of drugs from 1 or 2 new classes.

Here is compelling reason why every MD needs to test his or her patients for HCV, and get them into therapy as soon as possible.

Here’s a look at how emergency room experiences affect linkage to care and retention in care among patients with HIV.

Here: an update on progress and challenges in HIV eradication, and a focus on the efforts of the President’s Emergency Plan for AIDS Relief.

Is pre-exposure prophylaxis an effective means of reducing the number of new HIV infections?

Do we, in resource-rich countries, have the will and the resources to spend on HIV or HCV eradication? We have the tools (medications), but the goal of eradicating both infections seems as elusive as ever.

Details here about a quick reference guide for HIV primary care clinicians caring for HIV in older adults.

These presentations provided a wealth of data suggesting that very early treatment of HIV may help control viremia and achieve remission over time in pediatric patients.

Here: 4 subgroups of HIV patients whose cardiovascular health might benefit from your targeted intervention.

Useful details here about HIV and age-related issues, sexual dysfunction, heart disease, and end-organ damage.

These suggestions will enhance your enjoyment of long meetings and will have your colleagues remarking on what a jolly, friendly person you really are. Ignore the advice at your own peril.

The good: this premier HIV conference offers a banquet of exceptional material. The bad: the expense and the grind of covering a meeting this rich-and lengthy.

Two studies demonstrate that raltegravir is an extremely well-tolerated and potent component of a combination antiretroviral regimen.

Replication of HIV within the CNS continues to be a hot topic, because it represents a viral reservoir that can complicate treatment, as well as control and prevention efforts.

“Super-spreaders” continue to play a major role in various epidemics, including tuberculosis and HIV infection.

Preliminary study results confirm that patient education and targeting those in higher-risk populations or who engage in high-risk behaviors continue to be important in preventing HIV transmission. Four specific recommendations here.

It is quite likely that we have entered a new era of treatment for individuals either mono-infected with HCV or co-infected with HCV/HIV. Details here.

The START trial is likely to provide a definitive answer to one of the most important clinical questions in HIV management: when is the optimal time to start antiretroviral therapy.